Literature DB >> 15554419

Pathophysiology and clinical features of Wilson disease.

Peter Ferenci1.   

Abstract

Wilson disease is an autosomal recessive inherited disorder of copper metabolism resulting in pathological accumulation of copper in many organs and tissues. ATP7B is the gene product of the Wilson disease gene located on chromosome 13 and resides in hepatocytes in the trans-Golgi network, transporting copper into the secretory pathway for incorporation into apoceruloplasmin and excretion into the bile. Mutations of the gene result in impaired trafficking of copper in and through the hepatocytes. More than 200 mutations of Wilson disease gene were found, the most common ones being H1069Q (in Europe) and R778L (in Asia). Wilson disease may present under a variety of clinical conditions, commonly as liver and/or neuropsychiatric disease. The pathogenesis of hepatic and neurologic Wilson disease is a direct consequence of copper accumulation. Presence of copper causes oxidative stress resulting in cell destruction. The diagnosis of Wilson disease requires a combination of a variety of clinical symptoms, biochemical tests, and detection of gene mutations, which are the basis of a score proposed by a group of international experts. Initial treatment for symptomatic patients should include a chelating agent (penicillamine or trientine). Treatment of presymptomatic patients or maintenance therapy can also be accomplished with zinc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554419     DOI: 10.1023/b:mebr.0000043973.10494.85

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  56 in total

1.  Undetectable intracellular free copper: the requirement of a copper chaperone for superoxide dismutase.

Authors:  T D Rae; P J Schmidt; R A Pufahl; V C Culotta; T V O'Halloran
Journal:  Science       Date:  1999-04-30       Impact factor: 47.728

2.  Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction.

Authors:  V Yuzbasiyan-Gurkan; A Grider; T Nostrant; R J Cousins; G J Brewer
Journal:  J Lab Clin Med       Date:  1992-09

Review 3.  Perspectives on Wilson's disease.

Authors:  I Sternlieb
Journal:  Hepatology       Date:  1990-11       Impact factor: 17.425

4.  Evoked potentials in assessment and follow-up of patients with Wilson's disease.

Authors:  G Grimm; W Oder; L Prayer; P Ferenci; C Madl
Journal:  Lancet       Date:  1990-10-20       Impact factor: 79.321

Review 5.  The elusive function of metallothioneins.

Authors:  R D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

6.  The response of neurones and glial cells to elevated copper.

Authors:  N T Watt; N M Hooper
Journal:  Brain Res Bull       Date:  2001-05-15       Impact factor: 4.077

7.  Screening for Wilson's disease in patients with liver diseases by serum ceruloplasmin.

Authors:  E Cauza; T Maier-Dobersberger; C Polli; K Kaserer; L Kramer; P Ferenci
Journal:  J Hepatol       Date:  1997-08       Impact factor: 25.083

8.  Metallochaperone Atox1 transfers copper to the NH2-terminal domain of the Wilson's disease protein and regulates its catalytic activity.

Authors:  Joel M Walker; Ruslan Tsivkovskii; Svetlana Lutsenko
Journal:  J Biol Chem       Date:  2002-05-23       Impact factor: 5.157

9.  Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (From the National Hospital, and the Laboratory of the National Hospital, Queen Square, London) Brain 1912: 34; 295-509.

Authors:  Alastair Compston
Journal:  Brain       Date:  2009-08       Impact factor: 13.501

10.  Molecular characterization of wilson disease in the Sardinian population--evidence of a founder effect.

Authors:  G Loudianos; V Dessi; M Lovicu; A Angius; A Figus; F Lilliu; S De Virgiliis; A M Nurchi; A Deplano; P Moi; M Pirastu; A Cao
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

View more
  34 in total

Review 1.  [Acute Wilson disease].

Authors:  D Huster; W Hermann; M Bartels
Journal:  Internist (Berl)       Date:  2011-07       Impact factor: 0.743

2.  Molecular and biochemical characterization of a unique mutation in CCS, the human copper chaperone to superoxide dismutase.

Authors:  Peter Huppke; Cornelia Brendel; Georg Christoph Korenke; Iris Marquardt; Anthony Donsante; Ling Yi; Julia D Hicks; Peter J Steinbach; Callum Wilson; Orly Elpeleg; Lisbeth Birk Møller; John Christodoulou; Stephen G Kaler; Jutta Gärtner
Journal:  Hum Mutat       Date:  2012-05-16       Impact factor: 4.878

3.  Hepatocyte GP73 expression in Wilson disease.

Authors:  Lorinda M Wright; Dominik Huster; Svetlana Lutsenko; Fritz Wrba; Peter Ferenci; Claus J Fimmel
Journal:  J Hepatol       Date:  2009-06-25       Impact factor: 25.083

Review 4.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 5.  Classification and differential diagnosis of Wilson's disease.

Authors:  Wieland Hermann
Journal:  Ann Transl Med       Date:  2019-04

6.  Homozygosity for Non-H1069Q Missense Mutations in ATP7B Gene and Early Severe Liver Disease: Report of Two Families and a Meta-analysis.

Authors:  Julnar Usta; Hussein Abu Daya; Houssam Halawi; Ibraheem Al-Shareef; Omar El-Rifai; Ahmad H Malli; Ala I Sharara; Robert H Habib; Kassem Barada
Journal:  JIMD Rep       Date:  2011-11-08

7.  Allantoin in human urine quantified by ultra-performance liquid chromatography-tandem mass spectrometry.

Authors:  Adviye A Tolun; Haoyue Zhang; Dora Il'yasova; Judit Sztáray; Sarah P Young; David S Millington
Journal:  Anal Biochem       Date:  2010-03-31       Impact factor: 3.365

8.  Mutations in SLC33A1 cause a lethal autosomal-recessive disorder with congenital cataracts, hearing loss, and low serum copper and ceruloplasmin.

Authors:  Peter Huppke; Cornelia Brendel; Vera Kalscheuer; Georg Christoph Korenke; Iris Marquardt; Peter Freisinger; John Christodoulou; Merle Hillebrand; Gaele Pitelet; Callum Wilson; Ursula Gruber-Sedlmayr; Reinhard Ullmann; Stefan Haas; Orly Elpeleg; Gudrun Nürnberg; Peter Nürnberg; Shzeena Dad; Lisbeth Birk Møller; Stephen G Kaler; Jutta Gärtner
Journal:  Am J Hum Genet       Date:  2012-01-13       Impact factor: 11.025

9.  MR imaging of the brain in Wilson disease of childhood: findings before and after treatment with clinical correlation.

Authors:  T J Kim; I O Kim; W S Kim; J E Cheon; S G Moon; J W Kwon; J K Seo; K M Yeon
Journal:  AJNR Am J Neuroradiol       Date:  2006 Jun-Jul       Impact factor: 3.825

10.  Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study.

Authors:  Gudlaug Tórsdóttir; Grétar Gudmundsson; Jakob Kristinsson; Jón Snaedal; Torkell Jóhannesson
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.